According to a BBC News report earlier today, abiraterone acetate has been approved for use by National Health Service (NHS) patients with metastic, castration-resistant prostate cancer (mCRPC) in Northern Ireland. A decision about availability of the drug in Scotland is expected on August 13. Abiraterone is already available to NHS patients in England and in Wales.
Filed under: Management, Treatment | Tagged: abiraterone, access, UK | 1 Comment »
According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, access, NICE, UK | 1 Comment »
Dendreon’s production ramp-up for sipuleucel-T (Provenge®) is on track, the company says, with manufacturing expected to be up to full speed by year’s end. All three US-based manufacturing plants will be shipping by then, and treatment with Provenge should be available at hundreds of more locations, according to a Reuters report last week. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: access, Provenge, sipuleucel-T | Leave a comment »
The costs of first-line prostate cancer treatment for uninsured men (in America as well as elsewhere) are high: anywhere from $17,000 for a course of radiation therapy upwards, depending on the center you go to and the physicians you see. … READ MORE …
Filed under: Management, Treatment | Tagged: access, underinsured, uninsured | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 